

Resource Summary Report

Generated by [RRID](#) on Aug 31, 2026

MKN1

RRID:CVCL_1415

Type: Cell Line

Proper Citation

RRID:CVCL_1415

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1415

Proper Citation: RRID:CVCL_1415

Description: Cell line MKN1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Gastric adenosquamous carcinoma

Defining Citation: [PMID:758928](#), [PMID:1370612](#), [PMID:1778766](#), [PMID:1933850](#), [PMID:6862145](#), [PMID:9290701](#), [PMID:11107048](#), [PMID:15723654](#), [PMID:15767549](#), [PMID:15900046](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22336246](#), [PMID:22460905](#), [PMID:24807215](#), [PMID:25343454](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29435981](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:32847597](#), [PMID:34331011](#)

Comments: Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: JFCR45 cancer cell line panel., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MKN1

Synonyms: MKN-1, MKN 1

Cross References: BTO:BTO_0002384, CLO:CLO_0050804, EFO:EFO_0002830, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN03473129, BioSample:SAMN10987827,

cancercelllines:CVCL_1415, Cell_Model_Passport:SIDM00271, CGH-DB:117-1, CGH-DB:9019-4, ChEMBL-Cells:ChEMBL3307492, ChEMBL-Targets:ChEMBL614352, Cosmic:733174, Cosmic:801337, Cosmic:848145, Cosmic:848379, Cosmic:887252, Cosmic:888824, Cosmic:897532, Cosmic:908138, Cosmic:922692, Cosmic:926111, Cosmic:1007600, Cosmic:1090459, Cosmic:1093296, Cosmic:1187282, Cosmic:1223586, Cosmic:1436023, Cosmic:1482076, Cosmic:1627263, Cosmic:1995508, Cosmic:2443801, Cosmic:2484957, Cosmic:2807632, Cosmic-CLP:908138, DepMap:ACH-000351, EGA:EGAS00001000610, EGA:EGAS00001000978, FANTOM5_SSTAR:10614-108G2, GDSC:908138, GEO:GSM552363, GEO:GSM562394, GEO:GSM827531, GEO:GSM844606, GEO:GSM887323, GEO:GSM888399, GEO:GSM1374680, GEO:GSM1670111, IARC_TP53:998, JCRB:JCRB0252, KCLB:80101, LiGeA:CCLE_128, LINCS_LDP:LCL-1917, Lonza:1374, Pharmacodb:MKN1_936_2019, Progenetix:CVCL_1415, PubChem_Cell_line:CVCL_1415, RCB:RCB1003, Wikidata:Q54905820

ID: CVCL_1415

Record Creation Time: 20220427T220810+0000

Record Last Update: 20260829T234634+0000

Ratings and Alerts

No rating or validation information has been found for MKN1.

No alerts have been found for MKN1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 22 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Bandi DSR, et al. (2026) ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma. bioRxiv : the preprint server for biology.

Xie L, et al. (2026) Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor. Cancer discovery, 16(5), 895.

Kang M, et al. (2026) Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells. Molecular cancer therapeutics, 25(5), 814.

Pan G, et al. (2026) MTSS1-dependent ubiquitin modifications mediated by FBXO44 remodel the actin cytoskeleton to promote gastric cancer progression. Molecular cancer, 25(1).

Pan G, et al. (2026) Enhancing platinum-based chemotherapy efficacy and safety through combination therapy-mediated remodeling of autophagic homeostasis in gastric cancer. *Cell death & disease*, 17(1).

Nishikubo K, et al. (2025) Sustained reductions in valine and isoleucine mediate anti-cancer pharmacological effects of inhibiting amino acid transporter LAT1 in cancer cells. *Cancer & metabolism*, 13(1), 46.

Tedeschi A, et al. (2025) Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification. *Molecular cancer therapeutics*, 24(4), 550.

Foote JB, et al. (2025) A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer. *Cancer research*, 85(5), 956.

Urbanska M, et al. (2025) De novo identification of universal cell mechanics gene signatures. *eLife*, 12.

Kwiatkowski N, et al. (2025) CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers. *Cell chemical biology*, 32(4), 556.

Huang Z, et al. (2025) An LCN2-Dependent Positive-Feedback Loop Between Gastric Cancer Cells and Tumor-Associated-Macrophages Mediates Lymphangiogenesis and Lymphatic Metastasis. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e08352.

Wang P, et al. (2025) Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312. *Cancer research communications*, 5(5), 792.

Sasahara M, et al. (2024) Therapeutic antibody targeting natriuretic peptide receptor 1 inhibits gastric cancer growth via BCL-2-mediated intrinsic apoptosis. *International journal of cancer*, 154(7), 1272.

Dietrich C, et al. (2024) INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors. *Cancer discovery*, 14(3), 446.

Kim B, et al. (2024) Predictive biomarkers for metachronous gastric cancer development after endoscopic resection of early gastric cancer. *Cancer medicine*, 13(16), e70104.

Stanland LJ, et al. (2023) CBF-Beta Mitigates PI3K-Alpha-Specific Inhibitor Killing through PIM1 in PIK3CA-Mutant Gastric Cancer. *Molecular cancer research : MCR*, 21(11), 1148.

Zhang X, et al. (2022) Kinase DYRK2 acts as a regulator of autophagy and an indicator of favorable prognosis in gastric carcinoma. *Colloids and surfaces. B, Biointerfaces*, 209(Pt 1), 112182.

Tanaka H, et al. (2022) Transcriptomic profiling on localized gastric cancer identified CPLX1 as a gene promoting malignant phenotype of gastric cancer and a predictor of recurrence after surgery and subsequent chemotherapy. *Journal of gastroenterology*,

57(9), 640.

Umeda S, et al. (2022) Lysosomal-associated membrane protein family member 5 promotes the metastatic potential of gastric cancer cells. *Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association*, 25(3), 558.

Sakai H, et al. (2021) Folate receptor ?? increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb-202 in gastric cancer. *Clinical and translational medicine*, 11(6), e454.